$13.46
AxoGen


Performance
Dividends
1W
1M
YTD
1Y
3Y
13/36
Growth
Score
12/36
Dividend
Score
Valuation
PE Ratio
-84.94
PS Ratio
3.15
RSI
-
0
PEG Ratio
0
3
PRG Ratio
0.17
PDG Ratio
0
Growth
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
3
Rule
of 40
90.28%
2
Gross Margin
74.18%
3
Current Ratio
4.28
Return on Assets
-3.65%
Return on Equity
-7.09%
Return on inv. Capital
-0.27%
Institutional Holder
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2024 187.34M
2018
2019
2020
2021
2022
2023
2024
6
Net Income 2024 -9.96M
2018
2019
2020
2021
2022
2023
2024
6
Gross Profit 2024 141.98M
2018
2019
2020
2021
2022
2023
2024
6
Events

AXGN
AxoGen
in 284 days
before market open
Earnings per Share is expected with - and revenue with - .

AXGN
AxoGen
in 212 days
before market open
Earnings per Share is expected with - and revenue with - .

AXGN
AxoGen
in 102 days
before market open
Earnings per Share is expected with - and revenue with - .
About
Sector/Industry
Healthcare
Medical - Devices
IPO Date
17.12.1986
MaketCap
613.02M
Country
US
CEO
Michael D. Dale
Description
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Updated 23.07.2025